Skip to main content

Are you Dr. Sadeh?

Join over one million U.S. Physicians, Nurse Practitioners and PAs, already on Doximity.

  • Connect with colleagues in the same hospital or clinic
    You already have 39 invites waiting!
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

Claim this profile

Not you? Find your profile

Summary

  • Dr. Jonathan Sadeh, MD is an emergency medicine physician in New York, New York. He is currently licensed to practice medicine in New York and Massachusetts.

Education & Training

  • Massachusetts General Hospital/BIDMC/Harvard Medical School
    Massachusetts General Hospital/BIDMC/Harvard Medical SchoolFellowship, Pulmonary Disease and Critical Care Medicine, 2000 - 2004
  • Boston University Medical Center
    Boston University Medical CenterResidency, Internal Medicine, 1996 - 1999
  • Icahn School of Medicine at Mount Sinai
    Icahn School of Medicine at Mount SinaiClass of 1996

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2005 - 2024
  • MA State Medical License
    MA State Medical License 1998 - 2011

Awards, Honors, & Recognition

  • Physician Practice Connections Recognition Program National Committee for Quality Assurance, 2011-2013
  • Patient-Centered Medical Home Recognition Program National Committee for Quality Assurance, 2011-2013

Publications & Presentations

PubMed

Press Mentions

  • New Zeposia (Ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple Sclerosis
    New Zeposia (Ozanimod) Data Highlight COVID-19 Outcomes and Preservation of Long-Term Cognitive Function from Separate Analyses in Patients with Relapsing Forms of Multiple SclerosisOctober 26th, 2022
  • New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (Ozanimod) Treatment Prevents Disease Relapse over One Year in 86.1% of Patients Who Respond at the End of the Induction Period
    New Data Presented at the American College of Gastroenterology Annual Scientific Meeting Demonstrate Continuous Zeposia (Ozanimod) Treatment Prevents Disease Relapse over One Year in 86.1% of Patients Who Respond at the End of the Induction PeriodOctober 24th, 2022
  • FDA Approves Drug Sotyktu for Treatment of Plaque Psoriasis
    FDA Approves Drug Sotyktu for Treatment of Plaque PsoriasisSeptember 10th, 2022
  • Join now to see all